A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer

医学 前列腺癌 养生 队列 中性粒细胞减少症 不利影响 内科学 毒性 肿瘤科 放射性核素治疗 临床研究阶段 贫血 临床终点 发热性中性粒细胞减少症 加药 癌症 队列研究 阿尔法(金融) 恩扎鲁胺 最大耐受剂量 性能状态 前瞻性队列研究 胃肠病学 前列腺 药代动力学
作者
Scott T. Tagawa,Charlene Thomas,Abdul Arham,Aaron Holmes,Valentina Marulanda Corzo,Tobechukwu Okobi,Shankar Vallabhajosula,Vasilios Avlonitis,Sandra Huicochea Castellanos,Jones Trevor Nauseef,Elisabeth O’Dwyer,Maham Fatima,Peter Gregos,Sarah Yuan,Cora Nanette Sternberg,Ana M. Molina,David M. Nanus,Neil Harrison Bander,Joseph R. Osborne
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:32 (20): 4552-4562 被引量:2
标识
DOI:10.1158/1078-0432.ccr-26-0689
摘要

PURPOSE: To test the safety of two regimens at differing levels of radioactivity of prostate-specific membrane antigen (PSMA)-targeted α-radionuclide 225Ac-J591. PATIENTS AND METHODS: Patients with progressive, metastatic androgen pathway modulation-resistant prostate cancer were enrolled in two parallel dose-escalation cohorts: (i) fractionated-dose regimen (single cycle of 45-65 KBq/kg of 225Ac-J591 on days 1 and 15; main cohort agnostic to prior receipt of 177Lu-PSMA and an additional cohort with prior receipt of 177Lu-PSMA) and (ii) multiple cycles of 225Ac-J591 (45-65 KBq/kg administered every 6 weeks for up to 4 cycles). PSMA PET was not utilized for eligibility. The primary endpoint was determination of dose-limiting toxicity (DLT) and recommended phase II dose (RP2D); the fractionated cohort was expanded. RESULTS: Forty-two patients were enrolled in the fractionated-dose regimen (23 dose-escalation, 11 dose-expansion, and 8 after 177Lu-PSMA) and 18 in multiple-dose regimen. All received ≥1 prior androgen receptor pathway inhibitor, 72% received chemotherapy, and 18% received 177Lu-PSMA. Three patients had DLTs in the fractionated regimen with RP2D of 60 KBq/kg twice. Seven had DLTs in the multiple-cycle regimen; this regimen is not recommended for further development. Among adverse events of special interest, temporary hematologic toxicity was most common [93% thrombocytopenia (32% grade >3), 65% neutropenia (13% grade ≥3), and 63% anemia (20% grade ≥3)]; dry mouth occurred in 62% (2% grade 2). Across fractionated cohorts with or without prior 177Lu-PSMA, a >50% prostate-specific antigen (PSA) decline was the best response occurring in 60% of patients; 28% had a >50% PSA decline in multiple cycles. CONCLUSIONS: Fractionated dosing of 225Ac-J591 seems promising. Further investigation is underway.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
海边的月亮完成签到,获得积分10
1秒前
1秒前
1秒前
隐隐完成签到,获得积分10
1秒前
十三发布了新的文献求助10
2秒前
2秒前
852的应助被猪猪猪采纳,获得10
3秒前
TOMORROW发布了新的文献求助10
3秒前
kk发布了新的文献求助10
4秒前
年轻映安发布了新的文献求助10
4秒前
5秒前
hiraabb完成签到 ,获得积分10
5秒前
xxxhhaoxxx发布了新的文献求助10
6秒前
00hello00发布了新的文献求助10
6秒前
寒鸦浮水完成签到,获得积分10
7秒前
独孤蚕完成签到,获得积分10
7秒前
隐隐发布了新的文献求助10
7秒前
炜豪发布了新的文献求助10
8秒前
科研通AI6.2的应助被匆匆采纳,获得10
8秒前
南科易梦发布了新的文献求助10
9秒前
菠萝完成签到 ,获得积分10
9秒前
Lucas的应助被乌贼爱吃采纳,获得10
10秒前
善良的汉堡完成签到 ,获得积分10
10秒前
mmm发布了新的文献求助10
10秒前
研友_VZG7GZ的应助被Yoghurt采纳,获得30
10秒前
10秒前
10秒前
11秒前
heng发布了新的文献求助38
11秒前
11秒前
雪白玲完成签到,获得积分10
11秒前
LYK完成签到,获得积分10
13秒前
苹果从梦完成签到,获得积分10
14秒前
Singel完成签到,获得积分10
14秒前
zzz完成签到 ,获得积分20
15秒前
15秒前
15秒前
syvshc的应助被Waitcy采纳,获得10
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194041
求助须知:如何正确求助?哪些是违规求助? 9579979
关于积分的说明 21868799
捐赠科研通 7793641
什么是DOI,文献DOI怎么找? 3437477
关于科研通互助平台的介绍 2560942
邀请新用户注册赠送积分活动 2484251